Increasing chromosome 1 copy number parallels histological progression in breast carcinogenesis by Cummings, M C et al.
It is generally accepted that invasive ductal carcinoma of the
breast arises from pre-existing ductal carcinoma in situ (DCIS)
and, reflecting this link, the grade of the invasive cancer often
parallels that of the associated in-situ component. Whether or not
ductal epithelial hyperplasia and atypical ductal hyperplasia
(ADH) are direct precursors of DCIS is less clear.
Many adenocarcinomas of the endometrium arise on a back-
ground of endometrial hyperplasia with and without atypia (Fox
and Buckley, 1982). In the cervix, squamous cell carcinoma
develops from an initially low grade and later high grade squa-
mous dysplasia before developing into in-situ and then invasive
malignancy (Buckley et al, 1982). Evidence for comparable
disease progression in the breast is largely based on epidemio-
logical studies. DCIS left untreated, is associated with a tenfold
risk of subsequently developing invasive carcinoma and that
occurs in the same area of the breast. Duct epithelial hyperplasia
and ADH are associated with 1.5- and 4.6-fold increased risk
respectively of later invasive malignancy, but in contrast to DCIS,
that later invasive disease can occur anywhere in either breast
(Page and Dupont, 1990). Hyperplasia and ADH of the breast thus
appear to be markers of an increased risk of invasive disease,
rather than obligate precursors, as is the case with DCIS.
Some recent studies have shown abnormalities occurring early
in the possible pathway of breast cancer evolution. Loss of
heterozygosity (LOH) has been demonstrated at a number of loci
in both hyperplasia and ADH (O’Connell et al, 1994; Lakhani et
al, 1995, 1996). This implies that at least some hyperplasias are
clonal or neoplastic proliferations.
Abnormalities of chromosome 1 are one of the commonest
chromosomal abnormalities to occur in invasive breast cancer,
demonstrated in up to 80% of cases, often with three or more
copies of the chromosome present (Heim and Mitelman, 1995).
Increased chromosome 1 copy number is not just a late change
occurring in aneuploid tumours, nor does it just occur in invasive
carcinomas. Harrison et al (1997) demonstrated that six of eight
cases of invasive breast cancer with chromosome 1 aneusomy
were aneuploid and conversely, that six of another eight cases with
a normal chromosome 1 complement were aneuploid. Earlier,
Harrison et al (1995) had shown that 18 of 21 cases of DCIS had
increased chromosome 1 copy number. These cases were predom-
inantly of high nuclear grade or showed comedo necrosis.
We sought to investigate whether chromosome 1 aneusomy
occurs in ductal epithelial hyperplasia and ADH and thus whether
it could have an early causal role in the development of breast
cancer. We also wished to see if there was a progression of chro-
mosome 1 abnormalities that paralleled the histological progres-
sion from normal, through hyperplasia and ADH to in-situ and
invasive disease, both overall and within individual patients.
MATERIALS AND METHODS
Tissue samples
Formalin-fixed, paraffin-embedded blocks from seven cases
which included both proliferative breast disease and carcinoma,
were selected from the files of the Institute of Pathology,
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Article no. bjoc.1999.1064, available online at http://www.idealibrary.com on Klinikum rechts der Isar. Tissue was diagnosed as normal, or
showing duct epithelial hyperplasia, ADH, DCIS or invasive
carcinoma. The criteria for distinguishing hyperplasia and ADH
were according to those of Page and Anderson (1987).
Hyperplastic foci showed increased cells, with disordered place-
ment, indistinct cell borders, irregular secondary spaces and
varied nuclear features. Classifying a lesion as ADH is notori-
ously difficult and there is significant interobserver variation. The
criteria used included groups of cells in which there was a sugges-
tion of sharply punched out secondary spaces but these were not
completely developed through the entire primary space. The cells
also showed more uniform placement, together with hyperchro-
masia and generally single small nucleoli. DCIS was subclassi-
fied into low, intermediate and high nuclear grade according to
the criteria of Schwartz et al (1997). The modified Bloom and
Richardson grading scheme of Nottingham was used for grading
the invasive ductal carcinoma (Elston, 1987).
While precisely defining a lesion as ADH may not always be
realistic, for practical purposes within this study, ADH lesions had
histological features intermediate between those of hyperplasia of
usual type and unequivocal DCIS. They were intermediate in
terms of nuclear placement, definition of cell boundaries and
shape of secondary spaces, as well as cytonuclear features.
Regions were assigned to histopathological categories by two
pathologists (MCC and MW) using a conference microscope.
Normal breast tissue was present in each block selected and this
was used as an internal control for the variation in signal number
that may occur with slight differences in section thickness.
Consecutive 5-mm serial sections were cut for haematoxylin and
eosin staining (H&E) or left unstained for fluorescence in situ
hybridization (FISH).
DNA probe
The probe CEP1, specific for the centromeric region of chromo-
some 1 (1q12 Spectrum Orange, Vysis, Stuttgart, Germany) was
used. The specificity of the probe was confirmed on metaphase
preparations from peripheral lymphocytes from a healthy donor.
Slide preparation and hybridization
FISH reactions were prepared with slight modifications of estab-
lished protocols (Zitzelsberger et al, 1994; Aubele et al, 1997). The
predigestion stages included: 70% formic acid for 15 min, incuba-
tion in 1 M NaSCN at 80°C, for 10 min, and Pronase digestion.
Five hundred microlitres of 0.5 mg ml–1 Pronase E in phosphate-
buffered saline (PBS) was applied to each tissue section, main-
tained on a warming box at 37°C, for approximately 5–7 min
(range 3–12 minutes). Each section was viewed periodically using
phase-contrast microscopy to assess the nuclear features of the
unstained sections. Tissue digestion was considered complete
when the nuclear outlines became crisply defined. Digestion was
stopped by rinsing the slides in PBS, followed by incubation in
glycine (2 mg ml–1 in PBS) for 30 min at room temperature. One
microlitre of CEP 1 probe (Vysis, Germany), 2 ml of purified water
and 7 ml of CEP hybridization buffer was used in hybridization.
Post-hybridization washing was performed at 43°C as previously
described (Zitzelsberger et al, 1994). Nuclei were counterstained
with 1 mg ml–1 4¢,6-diamidino-2-phenylindole (DAPI) in antifade
solution.
Image acquisition
For FISH analysis fields of view were selected comparing
hybridized and counterstained slides with immediately adjacent
H&E-stained serial sections allowing unambiguous assignment of
cells to specific histological categories. Fields of view were
scanned with a confocal laser scanning microscope LSM 410 (Carl
Zeiss, Jena) and a 100 ´ objective (Zeiss, PNF, NA 1.3, oil immer-
sion) was used. A sequence of confocal optical sections was taken
at axial distance of 0.5 mm, covering the full thickness of the histo-
logical section (Aubele et al, 1997). The FISH signals labelled
with spectrum orange were taken using excitation at 543 nm and
emission greater than 590 nm. The DAPI counterstain of the 
nuclei was excited at 364 nm and detected within the spectral
range 400–430 nm. A third fluorescence channel (excitation
488 nm, emission 515–565) was used to identify non-specific
background. Extended depth of view images were calculated from
the image sequences by maximum projection. Finally the resulting
images were overlayed on an RGB-display for signal counting.
Evaluation
Signal counting was performed by one person (MCC). Only
lesional cell nuclei were included and overlapping nuclei were
excluded. In addition, only signals of a similar size and intensity
were counted. Different entities were all geographically distinct
and were often located in different blocks. Normal fields were
assessed from each block to provide a control for possible varia-
tions in section thickness. The mean signal number per cell was
calculated by dividing the total number of hybridization signals by
the total number of nuclei counted. This gave an average chromo-
somal copy number for each histological entity and was best suited
to describe clonal changes overall. The signal distribution or the
percentage of cells with 0, 1, 2 or more than 2 signals per nucleus
was also determined. Nuclear truncation due to tissue sectioning
results in signal losses, making assessment of monosomy difficult.
Evaluating normal breast ducts and lobules in each tissue section
allowed chromosome under-representation to be defined (for this
study) as signal numbers significantly less than that demonstrated
for the corresponding normal tissue of that same section from that
same block.
Statistical analysis
Mean signal number was compared across the various tissue types
(normal and abnormal) using one-way analysis of variance
(ANOVA). The mean signal number for abnormal tissue was also
examined relative to the mean number in the normal tissue from
the same section (‘normalized’ means) to adjust for differences in
section thickness. Multivariate regression techniques were also
used to compare mean signal number in abnormal tissue, after
adjusting for the mean numbers in normal tissue from each section
(to adjust for section thickness). The Mantel–Haenszel extension
to the c2 statistic (Mantel and Haenszel, 1959) was used as a test
for trend across disease progression in the percentages of cells
with more than 2 signals per nucleus within each case.
RESULTS
Representative examples of the histopathological entities are
shown in Figure 1. Hyperplasia was either mild or moderate. The
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Figure 1 Haematoxylin and eosin stained sections showing normal breast
(A), duct epithelial hyperplasia (B), atypical duct hyperplasia (C), ductal
carcinoma in situ (D) and invasive duct carcinoma (E). Scale bar = 15 mm
Table 1 Number of microscopic fields and cells examined by FISH
Normal Hyperplasia ADH DCIS Invasive cancer
Case no. No. of blocks Fields Cells Fields Cells Fields Cells Fields Cells Fields Cells
1 1 5 239 7 424
2 3 14 801 10 512 7 356 10 600 10 516
3 3 16 398 6 231 14 819 5 271
4 3 14 624 14 878 6 158 10 244
5 3 13 830 8 403 6 406 8 256 7 149
6 2 13 888 14 814 6 426
7 2 12 549 6 168 6 407
Total 17 87 4329 65 3430 39 2414 24 1014 32 1180
Average 618 490 482 338 295nuclear grade of the DCIS generally paralleled the histological
grade of the corresponding invasive carcinoma. In case no. 3 the
invasive component was of mucinous type. For FISH assessment,
249 fields from 17 blocks were examined, with over 12000 nuclei
scored in total (Table 1 and Figure 2). The average number of cells
assessed for each entity ranged from 295 cells per patient for
invasive cancers, up to an average of 618 cells per patient for the
normal tissue. In total, more normal tissue was examined than
other histological types as this was to provide a control for each
block.
In Table 2, results from a simple analysis of mean signal number
for each histopathological entity is presented. The mean signal
number for normal cells was 1.14, for hyperplasia and ADH was
1.56 and 1.5 respectively, while values for DCIS, 1.95 and
invasive duct carcinoma 1.79 were higher. The differences in these
means are statistically significant (P < 0.001).
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Figure 2 FISH using chromosome 1 probe showing normal breast (A), duct
epithelial hyperblasia (B), atypical duct hyperplasia (C), ductal carcinoma in
situ (D) and invasive duct carcinoma (E)1208 MC Cummings et al
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To control for possible errors introduced by variations in section
thickness the mean signal number for each entity was normalized
relative to a mean signal number of one for the normal tissue
(Table 3). The results were not meaningfully different from those
presented in Table 2. Thus it was considered that variation in
section thickness had a negligible influence on the mean number
of signals detected.
The average number of signals for each entity within each case
is presented in Figure 3. Using the criterion for monosomy of
significantly fewer signals in lesional tissue than in the control
normal tissue from that same block, we were not able to demon-
strate monosomy in any of the cases. As suggested by Tables 2 and
3, values for hyperplasia and ADH, and those for DCIS and inva-
sive carcinoma each appear to cluster together in pairs.
The percentage of cells containing greater than 2 signals per
nucleus for each case is presented in Table 4. A few normal cells
had more than 2 signals per nucleus. Six of the seven cases showed
a significant trend towards an increasing proportion of cells with
more than 2 signals per nucleus with increasing histological
progression (P < 0.001). In case 3, no such trend was seen.
DISCUSSION
Benign proliferative disease of the breast is very common and only a
very small proportion of affected women go on to develop invasive
carcinoma. Certain histopathological features indicate the overall
degree of relative risk for this progression and these are based
largely on epidemiological studies. However, histopathological
Table 2 Analysis of mean signal number
95% Confidence
interval for mean
Standard Lower Upper
Diagnosis No. Mean deviation Standard bound bound
error
Normal 17 1.1361 0.1949 0.04727 1.0359 1.2363
Hyperplasia 9 1.5608 0.2874 0.09581 1.3399 1.7818
ADH 6 1.4992 0.4252 0.1736 1.0529 1.9454
DCIS 3 1.9499 0.4838 0.2793 0.7480 3.1518
Invasive 4 1.7944 0.5546 0.2773 0.9119 2.6868
Total 39 1.4201 0.4153 0.06650 1.2855 1.5547
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Figure 3 Average signal number per entity within each case. (Error bars = standard error of the mean)
Table 3 ‘Normalized’ mean signal number relative to the mean number in the normal tissue
95% Confidence
interval for
mean
Standard Standard
No. Mean deviation error Lower Upper Minimum Maximum
bound bound
Hyperplasia 9 1.362 0.1452 0.0489 1.2504 1.4736 1.12 1.56
ADH 6 1.349 0.1789 0.0730 1.1605 1.5369 1.18 1.56
DCIS 3 1.651 0.2839 0.1639 0.9465 2.3569 1.37 1.94
IDC 4 1.646 0.7158 0.3579 0.5075 2.7856 0.86 2.53
Total 22 1.449 0.3405 0.07259 1.2988 1.6007 0.86 2.53diagnoses are subject to significant interobserver variation. Also,
how closely histopathological progression accurately reflects
biological disease progression is unclear. Grade 1 (well-differenti-
ated) invasive cancers may arise from low grade DCIS, rather than
necessarily requiring a progression through intermediate and high
grade DCIS before invasion occurs (Lakhani, 1999). In other cases,
extensive high-grade DCIS may be present with minimal or no inva-
sive disease. Better knowledge of the underlying biology of prolifer-
ative breast disease and how it relates to both in situ and invasive
cancer may allow more accurate predictions about which patients
require earlier treatment intervention.
Some of the chromosomal abnormalities commonly demon-
strated in invasive breast cancers have also been demonstrated in
benign breast disease. Dietrich et al (1995) using short-term
cultures demonstrated chromosomal abnormalities in 31 of 45
cases of benign proliferative breast disease. Loss of heterozygosity
(LOH) was demonstrated in 15% of cases of hyperplasia of usual
type (O’Connell et al, 1994). Using microdissection, LOH was
demonstrated in 5/9 informative cases of ADH on chromosome
16q and on 2/8 informative cases on chromosome 17p (Lakhani
et al, 1995). LOH was also demonstrated in 0–13% of up to
23 cases of hyperplasia, including loci at 17q, 17p and 16q
(Lakhani et al, 1996).
Micale et al (1994) investigated chromosomal aneusomy in both
proliferative and malignant lesions of the breast, using pericen-
tromeric probes for FISH analysis on paraffin sections. Loss of
chromosome 1 was not identified in any case and gain was not
identified in any of the proliferative lesions but only in cases of
DCIS and invasive carcinoma. Visscher et al (1996) also studied
examples of both ductal and lobular carcinoma in situ together
with a range of proliferative breast lesions, using FISH on paraffin
sections. While 70% of the DCIS cases showed chromosomal
aneuploidy (including five of five patients who had concurrent
invasive disease) none of the proliferative lesions showed any
detectable chromosomal gains.
Chromosome 1 aneusomy however, has been demonstrated in
some examples of benign breast disease, including those with near
diploid DNA content (Verdoodt et al, 1994). A total of 8.6% of
nuclei from benign cases displayed more than 2 signals per
nucleus compared with 7% of nuclei from normal tissue. The mean
number of signals per nucleus was significantly different between
the benign cases and the ductal carcinomas, but not between the
nonductal carcinomas (lobular and special types) and benign
disease. The mean number of signals for the benign cases was
1.88–2.13, while for the carcinomas it ranged from 1.49 to 3.69.
Unlike Micale et al (1994) and Visscher et al (1996), but more in
keeping with the findings of Verdoodt et al (1994), we demon-
strated increased chromosome 1 copy number in hyperplasia as
well as in in situ and invasive malignancy. Due to truncation of
nuclei in paraffin sections, signal number under-representation
was consistently present, however, also assessing normal tissue
within each section allowed comparisons between the different
entities to be made. Compared with normal tissue, the mean signal
number for each entity overall was elevated. Interestingly, the
values for hyperplasia and ADH clustered together, as did those
for DCIS and invasive ductal carcinoma, rather than being evenly
positioned along a spectrum. When the mean signal number for
each entity was ‘normalized’ to a mean signal number of one for
normal tissue, this clustering of signal numbers was still evident.
While the sample number is relatively small, this implies that the
risk for the later development of invasive carcinoma for ADH is
similar to that for hyperplasia, at least in terms of the contribution
of chromosome 1. The biological contribution of increased
chromosome 1 copy number for in situ and invasive disease also
appeared similar, again implying that other genetic events are
important overall in defining an invasive phenotype.
In each case, except case 3, progression of signal number was
seen in parallel with histopathological progression. The sample
studied though may have been biased in that the cases were
selected to include a range of histological lesions. Chromosomal
abnormalities in the benign components of this study may have
been more frequent than in a group of patients who have hyper-
plasia alone. The invasive component of case 3 had a mucinous
phenotype, possibly reflecting a different biological basis.
Some variation in the average number of signals per nucleus
was seen between cases. A number of factors may explain this.
The length of time a specimen is in formalin affects the amount of
tissue shrinkage that occurs, therefore affecting nuclear size and
the number of signals present in a section. The degree of nuclear
enlargement both in benign and malignant tissues may vary both
within and between cases. The specific chromosomal abnormali-
ties underlying the increased copy number seen here most prob-
ably varied from case to case, again affecting the number of
signals detected. While chromosome 1 abnormalities are very
common in breast cancer, a range of mechanisms underlies this
(Heim and Mitelman, 1995).
Signal distribution was also used to assess signal count.
Detecting occasional normal cells with more than 2 signals per
nucleus probably represents misinterpretation of overlapping
nuclei. Again, except for case 3, where no significant trend was
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Table 4 Percentage of cells with more than two signals per nucleus
Normal Hyperplasia ADH DCIS Invasive Chi-squared P-value
trend
1 1.26 16.51 36.3 < 0.001
2 1.87 8.20 7.30 17.83 10.66 69.8 < 0.001
3 1.51 6.06 4.86 1.48 0.07 = 0.79
4 0.48 3.76 17.72 27.46 234 < 0.001
5 1.93 14.14 6.90 48.83 41.61 331.4 < 0.001
6 1.69 9.46 12.21 60.9 < 0.001
7 3.99 33.93 39.56 189.4 < 0.0011210 MC Cummings et al
British Journal of Cancer (2000) 82(6), 1204–1210 © 2000 Cancer Research Campaign
seen, in each of the other cases a significant trend was identified
within each case of an increasing percentage of cells with greater
than 2 signals per nucleus occurring in parallel with histopatho-
logical progression.
In summary, the results here support the concept that benign
proliferative breast disease is a biological precursor of in-situ and
invasive ductal cancer and that increased chromosome 1 copy
number is an early part of this process. The clustering of mean
signal counts for ADH with those for hyperplasia suggests in terms
of chromosome 1 that although an increased risk of invasive
malignancy is present, that ADH will not necessarily progress.
This is in keeping with epidemiological studies in which ADH
gives an increased risk for later invasive disease but anywhere in
either breast rather than at the original site at which the ADH
occurred. Perhaps these early changes indicate a field effect with
the accumulation of further genetic changes required for the later
development of in situ or invasive disease.
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